CJC-1295 No DAC 10mg Peptide

CJC-1295 No DAC, also known as Modified GRF (1-29), is a synthetic analog of growth hormone-releasing hormone (GHRH). It is designed to stimulate the pituitary gland to release growth hormone (GH) in a pulsatile manner, mimicking the body's natural GH release patterns. This peptide is specifically engineered without the Drug Affinity Complex (DAC), which allows for shorter half-life and more frequent dosing in research settings.

The primary focus of research involving CJC-1295 No DAC is to explore its potential in modulating growth hormone levels, with implications for understanding growth, metabolism, and aging processes. Volta Peptides offers this peptide in a 10mg vial for research purposes, emphasizing its utility in growth hormone research protocols. It is crucial to note that this product is strictly for research use and not for human consumption.

CJC-1295 without DAC is the tetrasubstituted GHRH(1-29) peptide with no albumin-binding group attached. It is more accurately named modified GRF(1-29), and that name is worth preferring, because calling it CJC-1295 invites the assumption that it shares the pharmacokinetics of the DAC-bearing construct it is named after. It does not, and the difference is roughly two orders of magnitude in half-life.

The four substitutions on the GHRH(1-29) backbone exist to resist degradation. D-alanine at position 2 blocks dipeptidyl peptidase-4, which cleaves native GHRH at exactly the point required for receptor activation. The remaining substitutions address other degradation and aggregation liabilities. Together they extend the half-life from the minutes of unmodified sermorelin to roughly half an hour, which is a meaningful improvement but not a transformation.

At the receptor the molecule is a full agonist at the GHRH receptor on pituitary somatotrophs, signalling through Gs and cyclic AMP. Because clearance remains rapid, receptor stimulation is brief and the resulting growth hormone secretion is a pulse rather than a plateau. That pulsatile character is the pharmacological argument made for this version over the DAC-bearing one: it more closely resembles the episodic pattern of endogenous secretion.

CJC-1295 No DAC functions by binding to the growth hormone-releasing hormone receptor (GHRHR) on the pituitary gland. This interaction stimulates the release of endogenous growth hormone, which subsequently influences various physiological processes. The absence of DAC in this peptide leads to a shorter half-life, allowing for more precise control over GH pulse frequency in experimental settings.

Research indicates that the pulsatile release of GH, as facilitated by CJC-1295 No DAC, is crucial for maintaining normal physiological functions such as growth, metabolism, and tissue repair. Studies in animal models have shown that this peptide can effectively increase GH levels, thereby providing a valuable tool for investigating GH-related pathways and mechanisms. (References: J. Endocrinol. Invest., 2010)

Studies have demonstrated that CJC-1295 No DAC can significantly elevate growth hormone levels in various animal models. This effect is attributed to its ability to enhance the amplitude of GH pulses rather than increasing the baseline GH secretion, which is a critical factor in mimicking physiological GH release patterns. (Reference: Endocrinology, 2007)

The research conducted using CJC-1295 No DAC has provided insights into the potential modulation of GH for therapeutic applications, although such applications remain strictly within the realm of research. The ability to control GH release patterns offers a unique opportunity to study the hormone's role in growth and metabolic regulation without the prolonged effects associated with DAC-bound analogs.

The role of CJC-1295 No DAC in metabolism has been a subject of extensive research. The pulsatile release of GH induced by this peptide has been shown to influence lipid and carbohydrate metabolism, potentially affecting body composition and energy expenditure. Animal studies suggest that GH pulses can enhance lipolysis and improve insulin sensitivity, although these findings are preliminary and require further investigation. (Reference: J. Clin. Endocrinol. Metab., 2009)

While these studies highlight the peptide's potential impact on metabolic processes, it is important to emphasize that these effects are observed in controlled research environments. The findings contribute to a broader understanding of how GH modulation can affect metabolic health and disease, providing a foundation for future research.

Research into the effects of CJC-1295 No DAC on aging processes has garnered interest due to the peptide's ability to modulate GH levels. GH is known to play a role in cellular regeneration and repair, and its decline with age is associated with various age-related conditions. Studies in animal models suggest that restoring GH pulsatility through peptides like CJC-1295 No DAC could potentially ameliorate some aspects of aging. (Reference: Aging Cell, 2011)

These studies provide a framework for understanding the complex relationship between GH and aging, although the translation of these findings to human aging remains speculative. The research underscores the importance of GH in maintaining physiological functions and highlights the potential of CJC-1295 No DAC as a tool for aging research.

This compound is properly modified GRF(1-29). It acquired the name CJC-1295 without DAC because it is the same peptide backbone as the DAC-bearing construct, minus the albumin-binding group. The naming convention implies the two are variants of one drug differing in duration, which materially understates the difference.

Reported half-lives differ by roughly two orders of magnitude: about half an hour against six to eight days. A molecule that clears in half an hour produces a discrete growth hormone pulse. A molecule that persists for a week produces continuous receptor stimulation. Those are different pharmacological interventions that happen to share a peptide sequence.

The practical consequence for reading the literature is direct: a study of CJC-1295 is almost always a study of the DAC-bearing construct, because that is the molecule that went into clinical investigation. Applying its findings to modified GRF(1-29) is an extrapolation across a two-order-of-magnitude difference in exposure.

CAS 863288-34-0 designates CJC-1295 with DAC. It is routinely printed on certificates for the version without DAC, because the two share a name and suppliers copy the identifier across.

The two molecules differ in mass by roughly 280 daltons, so the reported mass distinguishes them unambiguously. A certificate quoting the DAC CAS number beside a mass near 3368 is describing one molecule and reporting another, in exactly the same way TB-500 certificates quote the thymosin beta-4 CAS beside a heptapeptide mass.

As with that case, the reliable field is the mass, not the name and not the identifier. A material sold as the no-DAC version should report a mass near 3368; one reporting near 3647 carries the DAC group.

The case made for this version rests on physiology rather than on comparative trial data. Endogenous growth hormone secretion is episodic, and the intervals between pulses are thought to matter for downstream receptor sensitivity rather than being inert gaps.

A short-acting GHRH analogue produces a discrete pulse and then clears, which resembles that pattern more closely than continuous stimulation does. Whether this translates into any different outcome has not been established by head-to-head study, and the argument should be presented as mechanistic reasoning rather than as demonstrated superiority.

Material supplied for laboratory work is for in-vitro research use only. This compound has no approved indication in any jurisdiction and appears on prohibited lists in competitive sport.

Unlike the DAC-bearing construct, this peptide carries no reactive maleimide, so thiol-containing buffers and reducing agents do not compromise its identity. That makes it the more forgiving of the two to handle.

The C-terminal amide is part of the specification and the free acid differs by one dalton. As with other GHRH analogues, the reported mass is the field that establishes which molecule is actually present, and it is the field most worth checking on arrival.